Shree Ganesh Remedies growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025
+0.6%−13.7%
−10.7%−6.2%
−17.2%−17.0%
−23.1%−17.9%
−23.0%−19.6%
+8.2%+12.3%
+12.3%+18.9%
−22.5%—
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

SGRL₹639.75

Shree Ganesh Remedies Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLNOVARTINDPARNAXLABSHUKRAPHARSUNLOCMcap ₹822 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Revenue Growth—-13.7+0.6
EBITDA Growth—-6.2-10.7
EBIT Growth—-17.0-17.2
Net Income Growth—-17.9-23.1
EPS Growth—-19.6-23.0
Total Assets Growth—+12.3+8.2
Total Equity Growth—+18.9+12.3
Cash from Operations Growth——-22.5
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.